Literature DB >> 25469291

Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors.

Hilmi Kodaz1, Ilhan Hacibekiroglu1, Bulent Erdogan1, Esma Turkmen1, Hilmi Tozkir2, Dogan Albayrak3, Sernaz Uzunoglu1, Irfan Cicin1.   

Abstract

The aim of this study was to investigate the clinicopathological characteristics and distribution by tumor localization of KRAS point mutations in metastatic colorectal cancer. A total of 189 patients diagnosed with colorectal cancer between 2007 and 2014, who were either metastatic at the time of diagnosis or developed metastasis subsequently, were included in this study. KRAS mutation analysis was performed in the primary tumor tissues and KRAS mutations were identified in 47.6% of the patients. There was a high frequency of the p.G13D point mutation in left-colon tumors (P=0.011), while the p.G12D point mutation was more frequent in right-colon tumors (P=0.004). KRAS wild-type frequency (P=0.02) was higher among patients aged <40 years. A comparison of codon 12 and 13 mutations revealed that codon 12 mutations were more common in the >50-year-old group (P=0.03) and codon 13 mutations were more common in the <70-year-old group (P=0.04). KRAS wild-type tumors were localized in the right colon (P=0.005) and tumors with the p.G13D point mutation (P=0.018) were diagnosed at non-metastatic stages. In conclusion, KRAS point mutations in colorectal cancer exhibited a heterogeneous distribution in terms of tumor localization. In addition, the p.G13D point mutation was found to differ from other mutations in several aspects.

Entities:  

Keywords:  colorectal cancer; specific KRAS mutation; tumor location

Year:  2014        PMID: 25469291      PMCID: PMC4251110          DOI: 10.3892/mco.2014.448

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  22 in total

1.  Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer.

Authors:  W A Bleeker; V M Hayes; A Karrenbeld; R M Hofstra; J Hermans; C C Buys; J T Plukker
Journal:  Am J Gastroenterol       Date:  2000-10       Impact factor: 10.864

Review 2.  The KRAS oncogene: past, present, and future.

Authors:  Onno Kranenburg
Journal:  Biochim Biophys Acta       Date:  2005-10-25

3.  Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

Authors:  Wendy De Roock; Derek J Jonker; Federica Di Nicolantonio; Andrea Sartore-Bianchi; Dongsheng Tu; Salvatore Siena; Simona Lamba; Sabrina Arena; Milo Frattini; Hubert Piessevaux; Eric Van Cutsem; Chris J O'Callaghan; Shirin Khambata-Ford; John R Zalcberg; John Simes; Christos S Karapetis; Alberto Bardelli; Sabine Tejpar
Journal:  JAMA       Date:  2010-10-27       Impact factor: 56.272

4.  Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.

Authors:  Hubert Piessevaux; Marc Buyse; Michael Schlichting; Eric Van Cutsem; Carsten Bokemeyer; Steffen Heeger; Sabine Tejpar
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

5.  European cancer mortality predictions for the year 2014.

Authors:  M Malvezzi; P Bertuccio; F Levi; C La Vecchia; E Negri
Journal:  Ann Oncol       Date:  2014-04-23       Impact factor: 32.976

6.  Clinico-pathological study of K-ras mutations in colorectal tumors in Saudi Arabia.

Authors:  Ali Zahrani; Magdy Kandil; Talha Badar; Mahmoud Abdelsalam; Abdulla Al-Faiar; Abdelsalam Ismail
Journal:  Tumori       Date:  2014 Jan-Feb       Impact factor: 2.098

7.  Predominance of G to A codon 12 mutation K-ras gene in Dukes' B colorectal cancer.

Authors:  O Zulhabri; J Rahman; S Ismail; M R Isa; W N Wan Zurinah
Journal:  Singapore Med J       Date:  2012-01       Impact factor: 1.858

8.  Infrequent K-ras activation in superficial-type (flat) colorectal adenomas and adenocarcinomas.

Authors:  T Minamoto; K Sawaguchi; M Mai; N Yamashita; T Sugimura; H Esumi
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

9.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

10.  KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients.

Authors:  Carlos Gil Ferreira; Veronica Aran; Ilana Zalcberg-Renault; Ana Paula Victorino; Jonas H Salem; Martin H Bonamino; Fernando M Vieira; Mariano Zalis
Journal:  BMC Gastroenterol       Date:  2014-04-10       Impact factor: 3.067

View more
  9 in total

1.  KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer.

Authors:  Hilmi Kodaz; Ebru Taştekin; Bülent Erdoğan; İlhan Hacıbekiroğlu; Hilmi Tozkır; Hakan Gürkan; Esma Türkmen; Bora Demirkan; Sernaz Uzunoğlu; İrfan Çiçin
Journal:  Balkan Med J       Date:  2016-07-01       Impact factor: 2.021

2.  Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.

Authors:  Jacopo Martellucci; Giovanni Alemanno; Francesca Castiglione; Carlo Bergamini; Andrea Valeri
Journal:  Updates Surg       Date:  2015-02-22

3.  Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.

Authors:  Brinton Seashore-Ludlow; Matthew G Rees; Jaime H Cheah; Murat Cokol; Edmund V Price; Matthew E Coletti; Victor Jones; Nicole E Bodycombe; Christian K Soule; Joshua Gould; Benjamin Alexander; Ava Li; Philip Montgomery; Mathias J Wawer; Nurdan Kuru; Joanne D Kotz; C Suk-Yee Hon; Benito Munoz; Ted Liefeld; Vlado Dančík; Joshua A Bittker; Michelle Palmer; James E Bradner; Alykhan F Shamji; Paul A Clemons; Stuart L Schreiber
Journal:  Cancer Discov       Date:  2015-10-19       Impact factor: 39.397

4.  Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.

Authors:  Gretchen Glaser; S John Weroha; Marc A Becker; Xiaonan Hou; Sergio Enderica-Gonzalez; Sean C Harrington; Paul Haluska
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

5.  Association between clinicopathological features and survival in patients with primary and paired metastatic colorectal cancer and KRAS mutation.

Authors:  Xue-Lian Pang; Qiao-Xin Li; Zhi-Ping Ma; Yi Shi; Yu-Qing Ma; Xin-Xia Li; Wen-Li Cui; Wei Zhang
Journal:  Onco Targets Ther       Date:  2017-05-19       Impact factor: 4.147

6.  RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres.

Authors:  Annemarie Boleij; Véronique Tack; Aliki Taylor; George Kafatos; Sophie Jenkins-Anderson; Lien Tembuyser; Els Dequeker; J Han van Krieken
Journal:  BMC Cancer       Date:  2016-10-26       Impact factor: 4.430

7.  Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis.

Authors:  Lauren C Bylsma; Christina Gillezeau; Tamer A Garawin; Michael A Kelsh; Jon P Fryzek; Laura Sangaré; Kimberly A Lowe
Journal:  Cancer Med       Date:  2019-12-19       Impact factor: 4.452

Review 8.  The Molecular Associations of Signet-Ring Cell Carcinoma in Colorectum: Meta-Analysis and System Review.

Authors:  Xueting Liu; Litao Huang; Menghan Liu; Zhu Wang
Journal:  Medicina (Kaunas)       Date:  2022-06-21       Impact factor: 2.948

9.  Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer.

Authors:  Aleksandra Bożyk; Paweł Krawczyk; Katarzyna Reszka; Kinga Krukowska; Agnieszka Kolak; Sławomir Mańdziuk; Kamila Wojas-Krawczyk; Rodryg Ramlau; Janusz Milanowski
Journal:  Arch Med Sci       Date:  2021-03-24       Impact factor: 3.707

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.